HTA Outcomes

Sixteen agencies. One search.

NICE appraisals, SMC advice, PBAC outcomes, French HAS ratings, German G-BA benefit assessments, New Zealand PTAC advice, the Nordic reimbursement records, Welsh AWMSG appraisals, Dutch package and GVS advice, Brazil's SUS incorporation decisions and Poland's reimbursement recommendations: 23,196 decisions across 6,580 molecules, linked so you can see where the same drug got a different answer in a different system. Two worked examples, pembrolizumab and semaglutide, are free to explore in full; the rest of the archive is in the subscription. Where the same drug got a different answer in a different system, we flag it.

, decisions
, molecules
16agencies + EU JCA · UK · SCO · WAL · AUS · FRA · GER · ITA · ESP · NLD · NZL · SWE · DEN · NOR · BRA · POL · KOR
, cross-agency divergences

Base rates: what are the odds?

Computed from our full archive of 23,196 decisions back to 2000. Denominators are decided outcomes only (withdrawals, non-submissions and advice-only items excluded).

, NICE appraisals recommended
, SMC full submissions accepted
, PBAC decided outcomes recommended
, German assessments: no added benefit proven
, French ASMR dossiers rated V, "no improvement"
, PBAC deferrals that later became a yes
, rejected molecules eventually recommended
A data story · scroll it Four meetings to yes: eight tirzepatide verdicts on one timeline NICE and the SMC said yes with limits in 2023 and 2024. Australia's PBAC took until March 2026. Watch the whole arc →
Loading decisions…

What does this mean for your submission?

We read HTA precedent the way committees do: which comparators, which endpoints, which price signals swung past decisions in your indication. We build it into payer-ready models and value dossiers. Fixed fees, senior-built.

Talk to us about your asset